China's Biotech Supply Chain Advances: How the US Redraws the Safety Borders of the Biomedical Industry

US biotech policy is shifting.

Washington used to worry about whether Chinese contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and genomic testing and data services were finding their way into US government supply chains. The question has since grown: whether Chinese biotech companies are becoming a significant source of global drug innovation, and whether US capital, pharmaceutical licensing deals, and clinical data are in turn making China's biotech industry more competitive.

That is why the Biosecure Act, the COINS Act, and the Biotech Investment National Security Act (BINSA) have emerged one after another. Washington no longer sees Chinese biotech simply as a pool of low-cost suppliers; it now treats the sector as a question of economic security, medical resilience, and industrial sovereignty.

The toolkit has four layers.

The Biosecure Act governs federal procurement and grant-funded supply chains; the COINS Act regulates outbound US capital; BINSA seeks to bring biotech deals under outbound investment screening; and the Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) are pushing early-stage clinical trial reforms to make up for America's own slow pace of research.

Washington's priorities are changing. The aim used to be reducing the risks posed by Chinese suppliers; now it goes further, to keeping China from gaining access to US capital, clinical resources, and global commercialization channels. Biotech is entering an era of securitization.

The Pressure from Chinese Biotech Now Goes Beyond Low-Cost Supply

China’s biotech industry has moved up the value chain quickly in recent years, and its competitive edge no longer rests only on cheap research services and low manufacturing costs. Chinese drugmakers keep advancing in antibody-drug conjugates (ADCs), multispecific antibodies, oncology drugs, and early-stage clinical development, and multinational pharmaceutical companies have begun in-licensing drug assets from China in large numbers.

Pfizer’s collaboration with Innovent Biologics, worth up to $10.5 billion, and Bristol Myers Squibb’s deal with Jiangsu Hengrui Pharmaceuticals make it harder for Congress to treat such transactions as ordinary commercial business.

For big pharmaceutical companies, these deals make clear industrial sense. Facing patent cliffs and falling returns on R&D, they need faster, cheaper, and more clinically advanced assets to replenish their pipelines, and early-stage assets from Chinese drugmakers fit that need neatly.

From Congress's perspective, however, these deals may also carry long-term risks. Once US drugmakers fold Chinese research into their global pipelines, American capital, market access, clinical design, and commercialization capabilities could end up accelerating the rise of China's biotech industry.

China is no longer just a link in the supply chain; it is moving toward the source of innovation. That is the main backdrop to the shift in US policy.

Biosecure Act: Targeting Government Funding and Supply Chains First

The Biosecure Act is the first line of defense. Enacted as part of the National Defense Authorization Act (NDAA) for Fiscal Year 2026, it restricts the federal government, government contractors, and federal grant recipients from using equipment and services provided by "biotechnology companies of concern" in government contracts or grant-funded activities.

The law does not ban the US private sector from dealing with Chinese biotech firms; its direct reach is limited to federal procurement, government contracts, and grant funding. But US biotech is so intertwined with government money that universities, research institutions, health systems, military medicine programs, public health initiatives, and drug developers all have to re-examine their supply chains if federal funds are involved.

The key to the Biosecure Act is its list. The Office of Management and Budget (OMB) will draw up a list of "biotechnology companies of concern," which may be linked to national security tools such as the Department of Defense's 1260H "Chinese Military Companies" list. That makes the law not a one-off ban but a supply chain governance framework that will be updated as political, intelligence, and industry assessments change.

WuXi AppTec is the most prominent case. The company has long been deeply embedded in US drug development and manufacturing supply chains. If it faces tighter restrictions, US drugmakers, research institutions, and contractors will have to deal with technology transfers, quality validation, and rebuilt manufacturing processes, along with delays to development timelines.

The signal the Biosecure Act sends is unambiguous: wherever US public funds, military medicine, government procurement, or sensitive healthcare supply chains are involved, Chinese biotech service providers will face closer scrutiny.

COINS Act: From Supply Chain Security to Capital Controls

The second layer is the COINS Act. Passed in December 2025 as part of the NDAA for Fiscal Year 2026, it writes US controls on outbound investment into law and names five sectors: semiconductors and microelectronics, artificial intelligence, quantum information, high-performance computing and supercomputing, and hypersonic systems. Biotechnology is not yet formally covered, but BINSA, introduced in 2026, points clearly to the next step: bringing drug development, biologics manufacturing, and clinical research and development under outbound investment screening. Draft rules that the Treasury published on October 22, 2026, to implement the COINS Act would also bar US investment in certain biotechnologies; comments close on December 7, and the rules are not yet final.

The COINS Act matters because it moves the policy question from "Can the US use Chinese services?" to "Can US capital help upgrade Chinese industry?" The logic differs from that of the Biosecure Act: the Biosecure Act deals with supply chain dependence, while the COINS Act targets outflows of capital, technology, and managerial know-how.

If biotechnology is brought under outbound investment review, some licensing deals, joint ventures, equity investments, co-development agreements, and clinical collaborations may be subject to national security assessment. Deals would not necessarily be banned, but filing costs would rise, reviews would take longer, and boards would carry more risk.

For the biotech sector, this is new territory. The semiconductor industry has long been used to export controls, investment screening, and end-user restrictions, whereas drugmakers and biotech firms have long depended on global clinical trials, multicenter studies, licensing deals, and cross-border R&D. Now biotech is starting to come under the same kind of policy pressure as chips.

BINSA: China Licensing Deals Put Congress on Alert

BINSA is the new bill most worth watching. It would add biotechnology to the scope of COINS Act screening, covering drug development, biologics manufacturing, and clinical research and development.

Its timing is no surprise. Over the past few years, major US drugmakers have in-licensed large numbers of early-stage assets from China, placing the work of Chinese developers in their global pipelines. To the companies, this is pipeline management; to some members of Congress, it looks like US capital and market access helping Chinese biotech become internationally competitive.

Congressional concern centers on three points:

First, if US drugmakers take Chinese drug assets to global markets, that raises the valuations, R&D capabilities, and international profile of Chinese biotech firms.

Second, cheap and fast-moving early-stage assets from China may squeeze funding for US startups, particularly in hot fields such as oncology, ADCs, and multispecific antibodies.

Third, clinical data, development processes, and platform technologies may flow in both directions during collaboration, making it hard to tell ordinary commercial cooperation from the leakage of strategic technology.

If BINSA moves forward, the likeliest outcome is not a blanket ban but filing requirements, reviews, and risk tiers. Licensing prices, deal timelines, partnership structures, and data arrangements for China-sourced assets will all be reset.

Defensive Measures Are Not Enough: The US Must Accelerate Its Own R&D

If the US stops at the Biosecure Act, the COINS Act, and BINSA, its policy will be largely defensive. The problem is that China’s biotech competitiveness does not rest on state support alone; it also comes from fast clinical development, efficient patient recruitment, integrated supply chains, and coordinated regulation.

That is why HHS and the FDA are pursuing early-stage clinical trial reforms, including rolling Investigational New Drug (IND) submissions, earlier engagement with regulators, more flexible trial designs, and shorter lead times for first-in-human trials. The goal is simple: keep more early-stage human trials in the United States.

The reform matters a great deal to the US. If US clinical trials are expensive and slow to start, and dealings with the FDA are unpredictable, companies will naturally look for faster places to do research. Part of the appeal of China, Australia, and other markets is how quickly their systems move, not just what they cost.

To stay ahead in biotech, the US cannot simply keep Chinese assets out of American pipelines; it also has to make the United States an efficient place to run clinical trials again. Regulatory stability, patient recruitment, trial costs, data quality, and industrial capital will determine whether companies keep early-stage development at home.

For Companies, Compliance Is Now a Boardroom Issue

The policy shift will change corporate decision-making directly. Over the next two years, US drugmakers, biotech companies, venture capital firms, and research institutions will need to reassess their exposure to China:

First, supply chains must be audited. Any CRO, CDMO, genomic testing, clinical research, reagent, equipment, software, or data processing service that involves China or a potential company of concern needs to be inventoried.

Second, existing contracts must be reviewed. If collaborations involve federal funds, government procurement, military medicine, or public health programs, the Biosecure Act could influence vendor selection.

Third, licensing deals must factor in national security risk. In-licensing deals for Chinese assets that involve joint R&D, platform technologies, clinical data, equity investments, or control arrangements may come under review.

Fourth, alternative suppliers must be lined up early. CDMOs and CROs cannot be replaced overnight; technology transfer, process validation, quality documentation, and regulatory review all take time.

Fifth, boards must treat US-China biotech deals as a matter of long-term governance. Such deals are no longer just a licensing call for the business development team; they raise questions of compliance, national security, reputation, and supply chain resilience.

Chinese Biotech Firms Under Pressure to Adjust

Chinese drugmakers will also be forced to adapt. Until now, Chinese companies could secure capital, international clinical experience, and global market access through out-licensing deals with US pharma. If BINSA or similar screening advances, getting Chinese assets into US pharma pipelines will become more costly.

Three changes may follow:

First, Chinese companies will step up the search for partners in Europe, Japan, the Middle East, and the Global South to reduce their reliance on US deals.

Second, Chinese firms will put more weight on domestic clinical development, domestic insurance reimbursement, and commercializing drugs themselves, and rely less on out-licensing alone.

Third, high-quality Chinese assets will still enter global markets, but through more complex structures such as regional licensing, data segregation, third-country entities, or stricter compliance arrangements.

US regulatory pressure will add short-term uncertainty for Chinese biotech, but it may also push Chinese firms to diversify internationally faster. Unless the US improves its own R&D efficiency at the same time, controls alone may not stop Chinese biotech from going global.

Opportunities for Taiwan and the Asian Biomedical Sector

As the US redesigns its biotech supply chain, the opportunities for Asian industry will change too. If US drugmakers rely less on Chinese CROs, CDMOs, and clinical resources, other trusted locations in Asia could take on part of that demand.

Taiwan can position itself in four areas:

First, build trusted clinical data and patient recruitment capabilities, especially for Asian populations, precision medicine, oncology, and rare diseases.

Second, strengthen capabilities in cell and gene therapy, biologics, nucleic acid drugs, and high-specification CDMO services.

Third, build data governance, cybersecurity, and regulatory quality systems that meet US and EU requirements.

Fourth, form biomedical partnerships with Japan, South Korea, Singapore, and Australia to meet the demand created by US de-risking.

Taiwan should not see this shift simply as a US-China conflict. It is also an opportunity created by the reorganization of the global biomedical supply chain. If Taiwan can build a position on trusted clinical work, regulatory quality, and manufacturing capability, it could win a new role as the United States reduces its dependence on China.

Biotech Enters an Era of Securitization

On the surface, the debate at BIO 2026 was about whether deals to in-license Chinese drugs should be screened. The deeper question is how the US can stop China's biotech supply chain and innovation capacity from eroding its own industrial dominance.

The Biosecure Act targets government supply chains, the COINS Act sets up an outbound investment framework, BINSA seeks to bring biotech under capital screening, and HHS and the FDA are speeding up clinical trial reform. All four point the same way: the US is raising biotech from an ordinary pharmaceutical sector to a matter of national competition and economic security.

Whether the package works depends on whether the US can do four things at once: reduce its dependence on Chinese supply chains, control high-risk outbound capital, make early-stage clinical development more efficient, and build trusted alternative capacity.

If the US relies on restrictions alone, costs will rise and drug development may slow. Only by combining restrictions, screening, clinical reform, and stronger domestic supply chains into a single policy will it have a chance of keeping its global lead as Chinese biotech rises.

Biotech is entering an era of securitization. Drug licensing, clinical trials, CDMO selection, and data flows will all become part of national competition, for Taiwan and the wider Asian biomedical industry as much as for the United States.